The New Logic of M&A
Cheap capital and the scarcity of growth are changing the calculus for assessing acquisitions.
Joseph G Paul
May 8, 2014
The Pfizer Inc. company logo and the AstraZeneca Plc company logo, top, are seen on boxes of pharmaceutical products produced by the drug makers in this arranged photograph taken in London, U.K., on Friday, May 2, 2014. AstraZeneca Plc rejected Pfizer Inc.'s sweetened takeover proposal, saying the 63.1 billion-pound ($106.5 billion) offer fails to recognize the value of the promising experimental medicines under development by the U.K.'s second-biggest drugmaker. Photographer: Chris Ratcliffe/Bloomberg
Chris Ratcliffe/Bloomberg
